Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome
This study has been terminated.
( Sponsor terminated trial )
Study NCT00251511   Information provided by Veeda Oncology

First Received on November 8, 2005.   Last Updated on May 9, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelodysplastic Syndrome
Additional conditions recognized in this trial
Myelodysplastic Syndromes
Preleukemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Precancerous Conditions
Interventions listed in this trial
Arsenic Trioxide
Additional drug interventions recognized in this trial
Thalidomide
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Veeda Oncology
Cephalon


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services